Fundraising Fox
/Companies
Sign in

Antag Therapeutics

Copenhagen, DK · Founded 2017 · 23 employees on LinkedIn · 10 known investors

Find your way into Antag Therapeutics

Sign up to see every warm intro you have to Antag Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Antag Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.

BiotechHealthtech

Founders & leadership

Antag Therapeutics was founded in 2017 by Jens Juul Holst and Mette Rosenkilde.

JJJens Juul Holst
Jens Juul HolstFounder
MRMette Rosenkilde
Mette RosenkildeFounderMette Rosenkilde is a pharmacologist and researcher at Copenhagen University focused on G protein-coupled receptor biology and metabolic diseases; she founded Antag Therapeutics based on years of collaborative research at the university to develop novel treatments for dietary-related metabolic disorders.

Investors · 10

Novo Holdingslisted by Novo HoldingsHellerup · $1.1M – $54M

How we know: Novo Holdings's portfolio page · funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

Versant VenturesreportedSan Francisco · $250K – $5M

How we know: a partner's Signal profile · funding news · prnewswire.com · Not right? Tell us

Also in the syndicate · 6

Dawn BiopharmaExport and Investment Fund of DenmarkExport and Investment Fund of Denmark (EIFO)Longview VenturesPictetSR One

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries ADec 2024 · 2 sources

    Versant Ventures (lead), Dawn Biopharma, Export and Investment Fund of Denmark, Export and Investment Fund of Denmark (EIFO), Longview Ventures, Novo Holdings, Pictet, SR One

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Antag Therapeutics went on to found or lead other companies.

Mads Emil MatthiesenCo-FounderFounded CathVisionJayson DallasDirector Board of DirectorsFounded Aimmune Therapeutics

In the news

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officerglobenewswire.com · May 2026Antag Therapeutics Announces €80 Million Series A Financingprnewswire.com · Dec 2024

Frequently asked questions

What does Antag Therapeutics do?
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.
Who founded Antag Therapeutics?
Antag Therapeutics was founded by Jens Juul Holst, Mette Rosenkilde in 2017.
Who are Antag Therapeutics's investors?
Antag Therapeutics's investors include Broadview Ventures, Novo Holdings, SR One Capital Management, Versant Ventures.
Where is Antag Therapeutics headquartered?
Antag Therapeutics is headquartered in Copenhagen, DK.